Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

被引：2

作者：

Dima, Danai ^{[1
]}

Hu, Xiao ^{[2
]}

Dower, Joshua ^{[2
]}

Zhang, Diana ^{[3
]}

Comenzo, Raymond ^{[4
]}

Varga, Cindy ^{[4
]}

机构：

[1] Cleveland Clin Fdn, Hematol Oncol Div, 9500 Euclid Ave, Cleveland, OH 44195 USA

[2] Tufts Med Ctr, Hematol Oncol Div, Boston, MA 02111 USA

[3] Massachusetts Gen Hosp, Internal Med Div, Boston, MA 02114 USA

[4] Tufts Med Ctr, Div Hematol Oncol, John C Davis Myeloma & Amyloid Program, Boston, MA 02111 USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 05期

关键词：

AL; RESPONSES;

D O I：

10.1080/10428194.2021.2018585

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1246 / 1250

页数：5

共 19 条

[11] Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature [J].

Lecumberri, Ramon ;

Krsnik, Isabel ;

Askari, Elham ;

Sirvent, Maialen ;

Gonzalez-Perez, Marta S. ;

Escalante, Fernando ;

Pradillo, Virginia ;

Tamariz, Luis E. ;

Canovas, Veronica ;

Alegre, Adrian ;

Gironella, Mercedes ;

Gonzalez-Garcia, Maria E. ;

Infante, Maria S. ;

Lakhwani, Sunil ;

Martinez-Bilbao, Cristina ;

Dourdil, Victoria ;

Ramirez-Payer, Angel ;

Sarra, Jose ;

Cibeira, M. Teresa .

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (03) :163-167

[12] Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis [J].

Mikhael, Joseph R. ;

Schuster, Steven R. ;

Jimenez-Zepeda, Victor H. ;

Bello, Nancy ;

Spong, Jacy ;

Reeder, Craig B. ;

Stewart, A. Keith ;

Bergsagel, P. Leif ;

Fonseca, Rafael .

BLOOD, 2012, 119 (19) :4391-4394

[13] High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate [J].

Milani, Paolo ;

Fazio, Francesca ;

Basset, Marco ;

Berno, Tamara ;

Larocca, Alessandra ;

Foli, Andrea ;

Riva, Marcello ;

Benigna, Francesca ;

Oliva, Stefania ;

Nuvolone, Mario ;

Rodigari, Lara ;

Petrucci, Maria Teresa ;

Merlini, Giampaolo ;

Palladini, Giovanni .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) :900-905

[14] Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA [J].

Palladini, Giovanni ;

Kastritis, Efstathios ;

Maurer, Mathew S. ;

Zonder, Jeffrey ;

Minnema, Monique C. ;

Wechalekar, Ashutosh D. ;

Jaccard, Arnaud ;

Lee, Hans C. ;

Bumma, Naresh ;

Kaufman, Jonathan L. ;

Medvedova, Eva ;

Kovacsovics, Tibor ;

Rosenzweig, Michael ;

Sanchorawala, Vaishali ;

Qin, Xiang ;

Vasey, Sandra Y. ;

Weiss, Brendan M. ;

Vermeulen, Jessica ;

Merlini, Giampaolo ;

Comenzo, Raymond L. .

BLOOD, 2020, 136 (01) :71-80

[15] A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis [J].

Roussel, Murielle ;

Merlini, Giampaolo ;

Chevret, Sylvie ;

Arnulf, Bertrand ;

Stoppa, Anne Marie ;

Perrot, Aurore ;

Palladini, Giovanni ;

Karlin, Lionel ;

Royer, Bruno ;

Huart, Antoine ;

Macro, Margaret ;

Morel, Pierre ;

Frenzel, Laurent ;

Touzeau, Cyrille ;

Boyle, Eileen ;

Dorvaux, Veronique ;

Le Bras, Fabien ;

Lavergne, David ;

Bridoux, Frank ;

Jaccard, Arnaud .

BLOOD, 2020, 135 (18) :1531-1540

[16] Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study [J].

Sanchorawala, Vaishali ;

Sarosiek, Shayna ;

Schulman, Amanda ;

Mistark, Meredith ;

Migre, Mary Ellen ;

Cruz, Ramon ;

Sloan, J. Mark ;

Brauneis, Dina ;

Shelton, Anthony C. .

BLOOD, 2020, 135 (18) :1541-1547

[17] Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden [J].

Schwotzer, Rahel ;

Manz, Markus Gabriel ;

Pederiva, Stefanie ;

Waibel, Christine ;

Caspar, Clemens ;

Lerch, Erika ;

Flammer, Andreas J. ;

Brouwers, Sofie ;

Seeger, Harald ;

Heimgartner, Raphael ;

Fehr, Thomas ;

Rossi, Davide ;

Bianchi, Elena ;

Stussi, Georg ;

Ghilardi, Guido ;

Gerber, Bernhard .

HEMATOLOGICAL ONCOLOGY, 2019, 37 (05) :595-600

[18] Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review [J].

Shragai, Tamir ;

Gatt, Moshe ;

Lavie, Noa ;

Vaxman, Iuliana ;

Tadmor, Tamar ;

Rouvio, Ory ;

Zektser, Miri ;

Horowitz, Nethanel ;

Magen, Hila ;

Ballan, Mouna ;

Suru, Celia ;

Luttwak, Efrat ;

Levi, Shai ;

Ziv-Baran, Tomer ;

Avivi, Irit ;

Cohen, Yael C. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (02) :184-195

[19] Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population [J].

Van de Wyngaert, Zoe ;

Carpentier, Benjamin ;

Pascal, Laurent ;

Lionne-Huyghe, Pauline ;

Leduc, Isabelle ;

Srour, Micha ;

Vasseur, Michele ;

Demarquette, Helene ;

Terriou, Louis ;

Herbaux, Charles ;

Manier, Salomon ;

Bossard, Jean-Baptiste ;

Barbieux, Sarah ;

Chauvet, Paul ;

Willaume, Alexandre ;

Nudel, Morgane ;

Bories, Claire ;

Gibier, Jean-Baptiste ;

Facon, Thierry ;

Boyle, Eileen M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (03) :E24-E27

← 1 2 →